^
Association details:
| Biomarker: | EGFR mutation + CDKN2A mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer
Published date:
10/26/2020
Excerpt:
...cohort 1, LM patients were treated with osimertinib with CSF and plasma genotyping performed before the first dosing of osimertinib (baseline, n=45);...Concurrent CDK4 (2.8 versus 11.6 months, P=0.002) and CDKN2A (2.5 versus 9.6 month, P=0.04) mutation with EGFR sensitizing mutations indicated lower median iPFS.
DOI:
10.1016/j.jtho.2020.10.008
